Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart Roma (Unicatt); University Hospital of Cologne Cologne; Karolinska University Hospital Stockholm; Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto (IPO Porto); Copenhagen University Hospital Denmark = Københavns Universitetshospital Danmark (KUH); University Medical Center Groningen Groningen (UMCG); Hospital Universitario HM Sanchinarro Madrid, Spain; IRCCS Ospedale San Raffaele Milan, Italy; University Hospital Brno; Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Openbare Bibliotheek Brugge; University of Zagreb; University of Rijeka; La Paz University Hospital; Universidad de Ciego de Avila (UNICA); Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona (UAB); Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf Hamburg (UKE); VIB Belgium; Polytechnic University of Bari / Politecnico di Bari; Institute of Public Health of Republic of North Macedonia Skopje; University-Hospital Munich-Großhadern München; University of Debrecen; Istituto di chimica biomolecolare Padova, Italy (ICB); National Research Council of Italy; University of Szeged Szeged; Universidad de Navarra Pamplona (UNAV); Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute Milan; University of Athens Medical School Athens; Pontificia Universidad Católica Argentina (UCA); Hospital General Universitario "Gregorio Marañón" Madrid; Universidad de Sevilla = University of Seville; Univerzita Palackého Olomouci; Palacky University Olomouc; Innsbruck Medical University = Medizinische Universität Innsbruck (IMU); CHU Montpellier = Montpellier University Hospital; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Institut de Génétique Moléculaire de Montpellier (IGMM); Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM); Hopital Saint-Louis AP-HP (AP-HP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Wrocław Medical University; Università del Salento = University of Salento Lecce; Unit of Melanoma Medical Oncology Fondazione IRCCS Istituto Nazionale Tumori, Milan; Universidad de Salamanca España = University of Salamanca Spain; Amsterdam University Medical Centers (Amsterdam UMC); Newcastle University Newcastle; Dipartimento di Scienze e Innovazione Tecnologica Alessandria (DISIT); Università degli Studi del Piemonte Orientale - Amedeo Avogadro (UPO); Hospital Universitario Marqués de Valdecilla Santander; Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB); Human Tumor Immunobiology Unit Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Dokuz Eylül Üniversitesi = Dokuz Eylül University Izmir (DEÜ); Università degli studi di Parma = University of Parma (UNIPR); Institute of Plasma Physics, Association EURATOM (IPP PRAGUE); Czech Academy of Sciences Prague (CAS); Universidade Federal do Rio de Janeiro Brasil = Federal University of Rio de Janeiro Brazil = Université fédérale de Rio de Janeiro Brésil (UFRJ); University of Belgrade Belgrade; Marmara University Kadıköy - İstanbul; Università degli Studi di Brescia = University of Brescia (UniBs); Universidad de Burgos = University of Burgos; Università cattolica del Sacro Cuore Milano (Unicatt); Universitá degli Studi dell’Insubria = University of Insubria Varese (Uninsubria); King‘s College London; Università degli Studi di Milano = University of Milan (UNIMI); University of California San Diego (UC San Diego); University of California (UC); Universität zu Köln = University of Cologne; Clinique Turin
    • بيانات النشر:
      CCSD
      American Society of Hematology
    • الموضوع:
      2022
    • Collection:
      Université de Montpellier: HAL
    • نبذة مختصرة :
      International audience ; Limited data have been published on the epidemiology and outcomes of breakthrough COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 vaccination. Adult HM who received at least one dose of anti-SARS-CoV-2 vaccine and diagnosed with breakthrough COVID-19 between January 2021 and March 2022 and registered in EPICOVIDEHA were included in this analysis. A total of 1548 cases were included, mainly with lymphoid malignancies (1181 cases, 76%). After viral genome sequencing in 753 cases (49%), Omicron variant was prevalent (517, 68.7%). Most of the patients received at least two vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received specific treatment for COVID-19. After 30-days follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with Omicron variant was of 7.9%, comparable to that reported for the other variants. The 30-day mortality rate was significantly lower than in the pre-vaccine era (31%). In the univariable analysis, older age (p<0.001), active HM (p<0.001), severe and critical COVID-19 (p=0.007 and p<0.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (p<0.001). In the multivariable model, older age, active disease, critical COVID-19 and at least 2-3 comorbidities were correlated with a higher mortality, whereas the administration of monoclonal antibodies, alone (p<0.001) or combined with antivirals (p=0.009), was observed protective. While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals. EPICOVIDEHA (www.clinicaltrials.gov; National Clinical Trials identifier NCT04733729) is an international open web-based registry for patients with ...
    • الرقم المعرف:
      10.1182/blood.2022017257/1922289/blood.2022017257.pdf
    • الدخول الالكتروني :
      https://hal.science/hal-03791153
      https://hal.science/hal-03791153v1/document
      https://hal.science/hal-03791153v1/file/Breakthrough%20COVID-19%20in%20vaccinated%20patients%20with%20hematologic%20malignancies-%20results%20from%20EPICOVIDEHA%20survey.pdf
      https://doi.org/10.1182/blood.2022017257/1922289/blood.2022017257.pdf
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.805E98C6